Columbus Macro’s Regeneron Pharmaceuticals REGN Stock Holding History

Columbus Macro’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-319	Closed	-$202K	–	217
2025 Q1	$202K	Sell	319 -7	-2%	-$4.82K	0.03%	200
2024 Q4	$232K	Buy	+326	New	+$274K	0.03%	193
2023 Q2	–	Sell	-330	Closed	-$266K	–	174
2023 Q1	$266K	Sell	330 -5	-1%	-$3.77K	0.1%	159
2022 Q4	$242K	Sell	335 -10	-3%	-$7.38K	0.09%	160
2022 Q3	$238K	Buy	345 +2	+0.6%	+$1.26K	0.1%	162
2022 Q2	$203K	Buy	343 +10	+3%	+$6.5K	0.08%	173
2022 Q1	$233K	Buy	+333	New	+$211K	0.08%	161

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Columbus Macro's REGN Position: Q2 2025 in Review

Columbus Macro sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 319 shares — an estimated $202K sold.

Columbus Macro first reported a position in REGN in Q1 2022 and held it in 7 quarters. The position peaked at $266K in Q1 2023. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Columbus Macro reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Columbus Macro sold 319 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $202K.
Columbus Macro first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Columbus Macro's Regeneron Pharmaceuticals position peaked at $266K in Q1 2023.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Columbus Macro's 13F filing for Q2 2025, filed 23 Jul 2025.